Abstract: The present invention relates to novel compounds and their use in fragrance compositions. Novel hexahydro ethanochromene and related hexahydro ethanochromane compounds of the present invention are represented by formula: wherein R1 is hydrogen or methyl; R2 and R2? are identical and are hydrogen or methyl; R3 and R3? are identical and are hydrogen or methyl; R4 and R5 are independently hydrogen or methyl; R6 is methyl, ethyl, or isopropyl, with the proviso that when R1 is H, R2 and R3? form an alkylene bridge containing 1 or 2 carbon atoms, and wherein the broken line represents a single or double bond.

Abstract: A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal.

Abstract: A production method of fluorinated compounds, for producing a compound represented by formula (3) in a fluorine-based solution in a flow of fluorine gas after reaction of at least one type of compounds represented by formula (1) and at least one type of compounds represented by formula (2). Similarly, fluorinated compounds represented by formula (4) prepared by the fluorination of compounds obtained by the reaction of formula (1) and formula (2)?. The fluorinated polymers obtained by the polymerizations of formula (3) and (4) compounds are useful as an optical or electrical materials. wherein R1, R2, R3, R4, Rff1, Rff2, Rff3, Rff4, X, Y, Z, and n are defined in the specification respectively.

Abstract: Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol and especially its enantiomer (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-ol, as well as certain novel intermediates for use in such methods are disclosed.

Abstract: A method for improving the selectivity of a supported highly selective epoxidation catalyst comprising silver in a quantity of at most 0.17 g per m2 surface area of the support, which method comprises contacting the catalyst, or a precursor of the catalyst comprising the silver in cationic form, with a feed comprising oxygen at a catalyst temperature above 250° C. for a duration of up to 150 hours, and subsequently decreasing the catalyst temperature to a value of at most 250° C.; and a process for the epoxidation of an olefin, which process comprises contacting a supported highly selective epoxidation catalyst comprising silver in a quantity of at most 0.17 g per m2 surface area of the support, or a precursor of the catalyst comprising the silver in cationic form, with a feed comprising oxygen at a catalyst temperature above 250° C. for a duration of up to 150 hours, and subsequently decreasing the catalyst temperature to a value of at most 250° C.

Abstract: The present invention relates to a process for the production of statins, which are known as HMG-CoA reductase inhibitors. A few of the intermediate compounds for use in the process in accordance with the invention are novel compounds and the invention also relates to these novel intermediate compounds.

Abstract: Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione.

Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.

Abstract: The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.

Abstract: The invention provides compounds that are A-type procyanidins. The compounds can be prepared by reacting flavylium salts with catechins or analogs thereof, for example, under anhydrous conditions in alcohol.

Abstract: Benzofuran compounds which contain at least one detectable label selected from the group consisting of 131I, 123I, 124I, 125I, 76Br, 75Br, 18F, 19F, 11C, 13C, 14C and 3H are provided as amyloid imaging agents for detecting brain amyloid deposits as well as other amyloidogenic peptides associated with systemic or localized amyloidosis. Additionally, the compounds are useful for determining if patients, presenting with clinically confusing cases of dementia or presenting with mild cognitive impairment, have Alzheimer's disease. The compounds are additionally useful as surrogate markers for monitoring the efficacy of anti-amyloidosis therapies.

Abstract: The invention relates to a process for the epoxidation of an olefin comprising (a) reacting the olefin with hydrogen peroxide in the presence of methanol as solvent in at least two reaction stages to obtain a mixture (M-a) comprising olefin oxide, unreacted olefin, methanol and water, wherein between at least two reaction stages, olefin oxide is separated by distillation; (b) separating unreacted olefin from the mixture (M-a) by distillation to obtain a mixture (M-bi) comprising at least 80 wt.-% of olefin and a mixture (M-bii) comprising methanol, water and at least 7 wt.-% of olefin oxide; (c) separating olefin oxide from the mixture (M-bii) in at least one distillation stage to obtain a mixture (M-ci) comprising at least 99 wt.-% of olefin oxide and a mixture (M-cii) comprising water and at least 55 wt.-% of methanol; (d) separating methanol from the mixture (M-cii) in at least one distillation stage to obtain a mixture (M-di) comprising at least 85 wt.-% of methanol and up to 10 wt.

Abstract: The invention relates to compounds of the formula (I), in which R1, R2, R3, R4, Y and A have the meanings indicated, and to processes for the preparation thereof and to the use thereof for the preparation of medicaments.

Abstract: A compound represented by the following formula (1) or (2):

Abstract: The present invention relates to a process for the preparation of compounds of a 1,4-dialkyl-2,3-diol-1,4-butanedione by a acidic aldol condensation between an alkyl glyoxal and an ?-hydroxy ketone.

Abstract: Alcohols are catalytically oxidized to aldehydes, in particular to benzaldehyde and diformylfuran, which are useful as intermediates for a multiplicity of purposes. The invention also relates to the polymerization of the dialdehyde and to the decarbonylation of the dialdehyde to furan.

Abstract: A method for preparing a dianhydrohexitol diester composition, characterized in that it comprises a step which consists in esterifying a dianhydrohexitol composition with a carboxylic acid in the presence of an acid catalyst and hypophosphorous acid. Preferably, the hypophosphorous acid is introduced in an amount ranging between 0.05 and 2 wt. % of dianhydrohexitol, and in a hypophosphorous acid/acid catalyst weight ratio less than 1/1. The method enables novel dianhydrohexitol diester compositions, for example isosorbide diesters, isomannide and/or isoidide richer in diester(s) and/or less colored, useful in numerous industrial applications, in particular in plastic compositions, to be obtained.

Abstract: The invention relates to improved systems for recovery of alkylene oxide from feed streams containing the same in an alkylene oxide recovery column. The invention also relates to improved processes for recovery of alkylene oxide from feed streams containing the same in an alkylene oxide recovery column.

Abstract: This invention is a process for producing propylene oxide. The process comprises first contacting a titanium zeolite with a reaction feed comprising propylene, hydrogen peroxide, tertiary butyl alcohol, and water to produce a product stream comprising propylene, propylene oxide, propylene glycol, tertiary butyl alcohol, and water. The product stream is distilled to produce a first overhead stream comprising propylene and a first bottoms stream comprising propylene oxide, propylene glycol, tertiary butyl alcohol, and water. The first bottoms stream is distilled to produce a second overhead stream comprising propylene oxide and a second bottoms product stream comprising propylene glycol, tertiary butyl alcohol, and water. The second bottoms stream is distilled to produce a third overhead stream comprising an azeotrope of tertiary butyl alcohol and water and a third bottoms stream comprising propylene glycol and water.

Abstract: The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.